We are live on ! Find out more
ATYR

aTyr Pharma
ATYR

29 hedge funds and large institutions have $5.25M invested in aTyr Pharma in 2018 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.19% less ownership

Funds ownership: 2.71% → 2.52% (-0.19%)

6% less funds holding

Funds holding: 31 → 29 (-2)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

43% less capital invested

Capital invested by funds: $9.22M → $5.25M (-$3.97M)

Holders
29
Holders Change
-2
Holders Change %
-6.45%
% of All Funds
0.65%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
4
Increased
4
Reduced
3
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$156K
2
Citadel Advisors
Citadel Advisors
Florida
+$18.8K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$15.7K
4
Macquarie Group
Macquarie Group
Australia
+$10.4K
5
Two Sigma Investments
Two Sigma Investments
New York
+$2.64K

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$406K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$209K
3
BCM
Bridgeway Capital Management
Texas
-$83K
4
ARTA
A.R.T. Advisors
New York
-$35K
5
Millennium Management
Millennium Management
New York
-$26K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$2.15M – – –
PVMCV
2
Polaris Venture Management Co V
Massachusetts
$906K – – –
Viking Global Investors
3
Viking Global Investors
Connecticut
$686K – – –
Renaissance Technologies
4
Renaissance Technologies
New York
$678K +$156K +18,638 +24%
Vanguard Group
5
Vanguard Group
Pennsylvania
$163K -$209K -24,937 -51%
BlackRock
6
BlackRock
New York
$93K -$12.3K -1,468 -10%
GHCM
7
Glen Harbor Capital Management
California
$76K – – –
MCIM
8
Meadow Creek Investment Management
Georgia
$63K – – –
Acadian Asset Management
9
Acadian Asset Management
Massachusetts
$60K – – –
Two Sigma Investments
10
Two Sigma Investments
New York
$54K +$2.64K +315 +4%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$52K – – –
EP
12
Elkfork Partners
Oregon
$49K – – –
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$49K +$15.7K +1,878 +36%
BFM
14
Boothbay Fund Management
New York
$47K – – –
RCM
15
Riverhead Capital Management
Delaware
$40K – – –
TAM
16
Tyers Asset Management
Texas
$36K – – –
Citadel Advisors
17
Citadel Advisors
Florida
$16K +$18.8K +2,248 New
Northern Trust
18
Northern Trust
Illinois
$15K – – –
Macquarie Group
19
Macquarie Group
Australia
$9K +$10.4K +1,243 New
Two Sigma Advisers
20
Two Sigma Advisers
New York
$6K +$117 +14 +2%
Bank of America
21
Bank of America
North Carolina
$4K – – –
RE
22
RBC Europe
United Kingdom
$2.97K – – –
Morgan Stanley
23
Morgan Stanley
New York
$2K – – –
PAM
24
Panagora Asset Management
Massachusetts
$1K -$9.73K -1,162 -86%
AG
25
Artal Group
Luxembourg
– -$406K -35,714 Closed
1
2

ATYR Hedge Fund Activity: Q4 2018 in Review

29 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q4 2018, worth a combined $5.25M — down 43% from $9.22M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of ATYR and 4 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 4 added.

The largest buyer was Renaissance Technologies, adding an estimated $156K. The largest seller was Artal Group, exiting entirely with an estimated $406K sold.

  • 29 institutional investors held aTyr Pharma (ATYR) as of Q4 2018, down from 31 in Q3 2018.
  • Funds reported $5.25M of aTyr Pharma stock for Q4 2018, down 43% quarter-over-quarter.
  • 4 funds opened new aTyr Pharma positions in Q4 2018 and 6 closed out, a net change of -2 holders.
  • The largest aTyr Pharma buyer in Q4 2018 was Renaissance Technologies, an estimated $156K added.
  • The largest aTyr Pharma seller in Q4 2018 was Artal Group, an estimated $406K sold.

Based on aggregated 13F filings for Q4 2018.